C4 Therapeutics Completes Core Scientific Leadership Team to Accelerate the Discovery of Novel Therapeutics for Targeted Protein Degradation

Highlights Leadership in Biology, Chemistry, Discovery Sciences, Translational Sciences and Alliance Management CAMBRIDGE, Mass. — C4 Therapeutics (C4T) today announced details of the leadership team recruited to develop a new class of broadly applicable small molecule drugs for degrading disease-relevant proteins for therapeutic benefit. The leadership team includes Isabel Chiu, Ph.D. as Senior Vice President…

C4 Therapeutics Appoints Andrew Phillips, Ph.D. as Chief Scientific Officer

CAMBRIDGE, Mass.– C4 Therapeutics today announced the appointment of Andrew Phillips, Ph.D. as Chief Scientific Officer. Dr. Phillips joins from the Broad Institute of MIT and Harvard and will lead C4 Therapeutics’ research efforts and the development of proprietary therapeutics based on the Company’s groundbreaking Degronimid™ platform. The Degronimid™ technology utilizes highly selective small molecule…

C4 Therapeutics Enters Strategic Drug Discovery Collaboration in the Promising New Field of Targeted Protein Degradation

BOSTON, Mass.– C4 Therapeutics today announced that they will enter into a strategic collaboration with Roche to develop novel treatments in the field of targeted protein degradation (TPD) using C4’s Degronimid™ technology. C4’s Degronimids represent a new class of small molecules, TPD therapeutics, which target disease-causing proteins and facilitate their rapid destruction and clearance from…